Harris Anthony D, Samore Matthew H, Lipsitch Marc, Kaye Keith S, Perencevich Eli, Carmeli Yehuda
Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, and VA Maryland Health Care System, Baltimore, MD, USA.
Clin Infect Dis. 2002 Jun 15;34(12):1558-63. doi: 10.1086/340533. Epub 2002 May 23.
We aimed to illustrate the importance of control-group selection on the results of risk factor analysis for (1) imipenem-resistant Pseudomonas aeruginosa, (2) vancomycin-resistant enterococci (VRE), and (3) ampicillin-sulbactam-resistant Escherichia coli. Case patients were compared with 2 different control groups: patients with the susceptible form of the organism (type 1), and control patients among whom the case patients arose during the same period as the case patients (type 2). Comparison of case patients who had imipenem-resistant P. aeruginosa with type-1 control patients identified use of imipenem (odds ratio [OR], 27.1) and quinolones (OR, 3.25) as a risk factor for selection of antimicrobial resistance, and comparison of the same case patients with type-2 control patients identified imipenem (OR, 6.34). When case patients with VRE were compared with type-1 and with type-2 control patients, use of vancomycin was identified as a risk factor (OR, 4.38 and 2.77, respectively). Comparison of case patients who had ampicillin-sulbactam-resistant E. coli compared with type-1 control patients identified ampicillin-sulbactam (OR, 2.71) and quinolones (OR, 2.72), and comparison with type-2 control patients identified ampicillin-sulbactam (OR, 1.68). The selection of control patients from the potentially suboptimal control type 1 can falsely identify certain antibiotics and overestimate the OR of the resistance-defining antibiotic.
(1)耐亚胺培南铜绿假单胞菌、(2)耐万古霉素肠球菌(VRE)和(3)耐氨苄西林 - 舒巴坦大肠杆菌。将病例患者与2个不同的对照组进行比较:感染该病原体敏感型的患者(1型),以及与病例患者在同一时期出现的对照患者(2型)。耐亚胺培南铜绿假单胞菌的病例患者与1型对照患者比较,确定亚胺培南的使用(比值比[OR],27.1)和喹诺酮类药物(OR,3.25)是抗菌药物耐药性选择的危险因素,而相同病例患者与2型对照患者比较,确定亚胺培南(OR,6.34)。当VRE病例患者与1型和2型对照患者比较时,万古霉素的使用被确定为危险因素(分别为OR,4.38和2.77)。耐氨苄西林 - 舒巴坦大肠杆菌的病例患者与1型对照患者比较,确定氨苄西林 - 舒巴坦(OR,2.71)和喹诺酮类药物(OR,2.72),与2型对照患者比较,确定氨苄西林 - 舒巴坦(OR,1.68)。从潜在不太理想的1型对照中选择对照患者可能会错误地识别某些抗生素,并高估定义耐药性的抗生素的OR。